Kronos Bio axes nearly one-fifth of staff to preserve cash for two cancer programs

Kronos Bio is downsizing its workforce by 19% as part of broader restructuring efforts meant to save cash, so that the company can continue work on its programs in solid tumors and acute myeloid leukemia.

The US biotech plans to reduce its staff in a bid…
Click here to view original post